The antiarrhythmic medicine market in Canada is projected to experience a declining trend from 2024 to 2028. In 2023, sales stood at 18.1 million USD PPP. Over the forecast period, sales are expected to decrease progressively, with year-on-year declines: 3.43% in 2025, 3.55% in 2026, 3.68% in 2027, and 3.82% in 2028. The compound annual growth rate (CAGR) from 2024 to 2028 is estimated at -3.61%, indicating a steady market contraction.
Future trends to watch for include advancements in alternative therapies for arrhythmia, potential generic drug influences, and policies impacting pharmaceutical pricing in Canada. Monitor developments in personalized medicine and telehealth, as they could play significant roles in reshaping treatment approaches.
